Shire plc (SHPG) and Its Competitors Financial Results Comparison

We are contrasting Shire plc (NASDAQ:SHPG) and its rivals on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They are Biotechnology companies, competing one another.

Insider and Institutional Ownership

22.9% of Shire plc’s shares are owned by institutional investors. Comparatively, 50.88% of all Biotechnology’s companies shares are owned by institutional investors. On other hand Shire plc has 0.1% of its shares owned by company insiders versus an average of 8.18% insiders ownership for its competitors.


On first table we have Shire plc and its competitors’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Shire plc 0.00% 13.00% 7.20%
Industry Average 1,464.25% 88.44% 21.62%

Valuation & Earnings

In next table we are contrasting Shire plc and its competitors’ valuation, net profit and top-line revenue.

Net Income Gross Revenue Price/Earnings Ratio
Shire plc N/A N/A 21.44
Industry Average 34.08M 2.33M 58.78

With currently lower price-to-earnings ratio Shire plc is more affordable than its rivals.

Analyst Recommendations

Table 3 provides summary of current ratings for Shire plc and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Shire plc 0 1 0 2.00
Industry Average 1.17 1.78 2.01 2.68

With consensus target price of $196, Shire plc has a potential upside of 9.38%. As a group, Biotechnology companies have a potential upside of 173.20%. Shire plc’s strong consensus rating and high possible upside, looks like is making analysts believe that the company is more favorable than its competitors.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Shire plc and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Shire plc -3.11% -5.99% 1.27% 6.01% 18.67% 9.67%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Shire plc was less bullish than its rivals.


The Current Ratio and a Quick Ratio of Shire plc are 0.9 and 0.5. Competitively, Shire plc’s rivals have 7.68 and 7.52 for Current and Quick Ratio. Shire plc’s peers have better ability to pay short and long-term obligations than Shire plc.

Volatility & Risk

Shire plc is 1.00% less volatile than S&P 500 because the stock has a beta of 0.99. Competitively, Shire plc’s rivals are 70.08% more volatile than S&P 500, because of the 1.70 beta.


The annual dividend that Shire plc pay is $0.35 per share with a dividend yield of 0.2%. On the other side, 3.06% is the dividend yield of Shire plc’s competitors.


On 6 of the 6 factors Shire plc’s peers beat Shire plc.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.